Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus IRBESARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus IRBESARTAN AND HYDROCHLOROTHIAZIDE.
FILSPARI vs IRBESARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Irbesartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
200 mg orally once daily, with or without food.
Oral: 1 tablet (irbesartan 150 mg / hydrochlorothiazide 12.5 mg or irbesartan 300 mg / hydrochlorothiazide 12.5 mg or irbesartan 300 mg / hydrochlorothiazide 25 mg) once daily, with or without food. Maximum: irbesartan 300 mg/hydrochlorothiazide 25 mg daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Irbesartan: 11-15 hours; Hydrochlorothiazide: 6-15 hours. Steady state achieved in 3-5 days.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Irbesartan: primarily biliary (80%) and renal (20%); Hydrochlorothiazide: renal (≥95% as unchanged drug).
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB